German Statutory Reimbursement Listing for NeuroNode
| Stock | Control Bionics Ltd (CBL.ASX) |
|---|---|
| Release Time | 4 Mar 2026, 8:20 a.m. |
| Price Sensitive | Yes |
Control Bionics Secures German Statutory Reimbursement Listing for NeuroNode
- NeuroNode device included in German Statutory Health Insurance Medical Aids Directory
- Enables reimbursement eligibility across Germany's statutory health insurance funds
- Positions CBL to scale its NeuroNode-only distribution strategy across the German speaking region
Control Bionics Limited (ASX: CBL) has announced that its NeuroNode device has been formally included in the German Statutory Health Insurance Medical Aids Directory (Hilfsmittelverzeichnis) under ยง139 SGB V. The decision, issued by the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds), confirms that NeuroNode has met all regulatory, safety, quality and clinical requirements for reimbursement eligibility within Germany's statutory health insurance system. Germany represents the largest assistive technology market in Europe and one of the most structured reimbursement systems globally. Inclusion in the Hilfsmittelverzeichnis enables reimbursement eligibility across Germany's statutory health insurance funds, removes a key commercial barrier for distributor engagement, provides validation of safety, functionality and quality standards, and positions CBL to scale its NeuroNode-only distribution strategy across the German speaking region. This approval follows CE compliance and confirms that NeuroNode satisfies German-language information and quality requirements. With reimbursement eligibility secured, the Company will now appoint and activate a German distribution partner, submit pricing and contracting applications, and commence pilot installations to accelerate adoption. The German listing supports CBL's global pivot toward NeuroNode-only wholesale distribution, reducing reliance on direct-to-consumer AAC sales and enabling scalable partner-led growth.
This approval materially lowers the barrier to entry for distribution partners and supports our strategy of building a scalable NeuroNode-only wholesale business globally. It strengthens CBL's European market entry, supports future expansion into Austria and Switzerland, enhances distributor negotiations in other EU markets, and provides additional validation in ongoing global discussions.